Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;177(10):1400-1414.
doi: 10.7326/ANNALS-24-00610. Epub 2024 Sep 10.

Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review

Elisheva R Danan  1 , Catherine Sowerby  2 , Kristen E Ullman  2 , Kristine Ensrud  3 , Mary L Forte  4 , Nicholas Zerzan  2 , Maylen Anthony  2 , Caleb Kalinowski  2 , Hamdi I Abdi  4 , Jessica K Friedman  5 , Adrienne Landsteiner  2 , Nancy Greer  2 , Rahel Nardos  6 , Cynthia Fok  7 , Philipp Dahm  8 , Mary Butler  4 , Timothy J Wilt  9 , Susan Diem  1
Affiliations

Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review

Elisheva R Danan et al. Ann Intern Med. 2024 Oct.

Abstract

Background: Postmenopausal women commonly experience vulvovaginal, urinary, and sexual symptoms associated with genitourinary syndrome of menopause (GSM).

Purpose: To evaluate effectiveness and harms of vaginal estrogen, nonestrogen hormone therapies, and vaginal moisturizers for treatment of GSM symptoms.

Data sources: Medline, Embase, and CINAHL through 11 December 2023.

Study selection: Randomized controlled trials (RCTs) of at least 8 weeks' duration enrolling postmenopausal women with at least 1 GSM symptom and reporting effectiveness or harms of hormonal interventions or vaginal moisturizers.

Data extraction: Risk of bias and data extraction were performed by one reviewer and verified by a second reviewer. Certainty of evidence (COE) was assessed by one reviewer and verified by consensus.

Data synthesis: From 11 993 citations, 46 RCTs evaluating vaginal estrogen (k = 22), nonestrogen hormones (k = 16), vaginal moisturizers (k = 4), or multiple interventions (k = 4) were identified. Variation in populations, interventions, comparators, and outcomes precluded meta-analysis. Compared with placebo or no treatment, vaginal estrogen may improve vulvovaginal dryness, dyspareunia, most bothersome symptom, and treatment satisfaction. Compared with placebo, vaginal dehydroepiandrosterone (DHEA) may improve dryness, dyspareunia, and distress, bother, or interference from genitourinary symptoms; oral ospemifene may improve dryness, dyspareunia, and treatment satisfaction; and vaginal moisturizers may improve dryness (all low COE). Vaginal testosterone, systemic DHEA, vaginal oxytocin, and oral raloxifene or bazedoxifene may provide no benefit (low COE) or had uncertain effects (very low COE). Although studies did not report frequent serious harms, reporting was limited by short-duration studies that were insufficiently powered to evaluate infrequent serious harms.

Limitations: Most studies were 12 weeks or less in duration and used heterogeneous GSM diagnostic criteria and outcome measures. Few studies enrolled women with a history of cancer.

Conclusion: Vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may improve some GSM symptoms in the short term. Few long-term data exist on efficacy, comparative effectiveness, tolerability, and safety of GSM treatments.

Primary funding source: Agency for Healthcare Research and Quality and Patient-Centered Outcomes Research Institute. (PROSPERO: CRD42023400684).

PubMed Disclaimer

Conflict of interest statement

Disclosures: All relevant financial relationships have been mitigated. Disclosure forms are available with the article online.

Figures

Figure 1.
Figure 1.. Literature Flow Diagram
*Includes 4 publications [1 RCT] of vaginal estrogen and moisturizer, 2 publications [2 RCTs] of vaginal estrogen and testosterone, 2 publications [1 RCT] of vaginal estrogen, testosterone, and moisturizer
See this image and copyright information in PMC

References

    1. Portman DJ GM, Panel VATCC. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Climacteric. 2014;17(5):557–63. - PubMed
    1. Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference P. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Journal of Sexual Medicine. 2014;11(12):2865–72. - PubMed
    1. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clinic Proceedings, 2010. Elsevier: 87–94. - PMC - PubMed
    1. Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology. 2016;215(6):704–11. - PubMed
    1. Kingsberg S, Kellogg S, Krychman M. Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy. International Journal of Women’s Health. 2010;1:105–11. - PMC - PubMed

Publication types

MeSH terms